Dosing frequency/PD/efficacy relationship of MEN1611 in HER2 amplified, PIK3CA mutated, and refractory to Trastuzumab xenograft model of breast cancer.

被引：0
|
作者：
Fiascarelli, Alessio [1 ]
Merlino, Giuseppe [1 ]
Capano, Stefania [1 ]
Bressan, Alessandro [1 ]
Bigioni, Mario [1 ]
Pellacani, Andrea [2 ]
Binaschi, Monica [1 ]
Salerno, Massimiliano [1 ]
机构：
[1] Menarini Ric, Pomezia, Italy
[2] Menarini Ric, Florence, Italy
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1376
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
    Ilenia Migliaccio
    Marta Paoli
    Emanuela Risi
    Chiara Biagioni
    Laura Biganzoli
    Matteo Benelli
    Luca Malorni
    npj Breast Cancer, 8
  • [42] PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
    Migliaccio, Ilenia
    Paoli, Marta
    Risi, Emanuela
    Biagioni, Chiara
    Biganzoli, Laura
    Benelli, Matteo
    Malorni, Luca
    NPJ BREAST CANCER, 2022, 8 (01)
  • [43] Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA
    Garay, Joseph P.
    Smith, Rebecca
    Devlin, Kaylyn
    Hollern, Daniel P.
    Liby, Tiera
    Liu, Moqing
    Boddapati, Shanta
    Watson, Spencer S.
    Esch, Amanda
    Zheng, Ting
    Thompson, Wallace
    Babcock, Darcie
    Kwon, Sunjong
    Chin, Koei
    Heiser, Laura
    Gray, Joe W.
    Korkola, James E.
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [44] Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA
    Joseph P. Garay
    Rebecca Smith
    Kaylyn Devlin
    Daniel P. Hollern
    Tiera Liby
    Moqing Liu
    Shanta Boddapati
    Spencer S. Watson
    Amanda Esch
    Ting Zheng
    Wallace Thompson
    Darcie Babcock
    Sunjong Kwon
    Koei Chin
    Laura Heiser
    Joe W. Gray
    James E. Korkola
    Breast Cancer Research, 23
  • [45] PI3K inhibitors overcome resistance to HER2-targeted agents caused by PIK3CA mutations in HER2-amplified breast cancer cell lines
    Kataoka, Yu
    Minami, Hironobu
    Shimada, Hiroyuki
    Saijo, Nagahiro
    Hirai, Midori
    Mukohara, Toru
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [46] Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001)
    Nishimura, Reiki
    Arima, Nobuyuki
    Toyoshima, Satoshi
    Ohi, Yasuyo
    Anan, Keisei
    Sagara, Yasuaki
    Mitsuyama, Shoshu
    Tamura, Kazuo
    MOLECULAR AND CLINICAL ONCOLOGY, 2013, 1 (01) : 47 - 52
  • [47] Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2− advanced breast cancer: results from BOLERO-2
    Mary Ellen Moynahan
    David Chen
    Wei He
    Patricia Sung
    Aliaksandra Samoila
    Daoqi You
    Trusha Bhatt
    Parul Patel
    Francois Ringeisen
    Gabriel N Hortobagyi
    Jose Baselga
    Sarat Chandarlapaty
    British Journal of Cancer, 2017, 116 : 726 - 730
  • [48] Association of PIK3CA mutations with efficacy in HER2-positive first-line metastatic breast cancer: a meta-analysis
    Swain, Sandra
    Cortes, Javier
    Xu, Binghe
    Lambertini, Chiara
    Essioux, Laurent
    Knott, Adam
    Restuccia, Eleonora
    Madjar, Katrin
    De Haas, Sanne Lysbet
    CANCER RESEARCH, 2023, 83 (05)
  • [49] IMPACT OF PIK3CA MUTATIONS AND P95HER2 EXPRESSION ON THE OUTCOME OF HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS TREATED WITH A TRASTUZUMAB-BASED THERAPY
    Stasi, I.
    Fontana, A.
    Allegrini, G.
    Mazzanti, C.
    Lucchesi, S.
    Bona, E.
    Ferrarini, I.
    Salvadori, B.
    Falcone, A.
    Zavaglia, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
  • [50] Impact of PIK3CA mutations and p95HER2 expression on the outcome of HER2-positive metastatic breast cancer patients treated with a trastuzumab-based therapy
    Fontana, Andrea
    Allegrini, Giacomo
    al Zoubi, Mazhar
    Collecchi, Paola
    Mazzanti, Chiara
    Stasi, Irene
    Lucchesi, Sara
    Bona, Eleonora
    Ferrarini, Ilaria
    Salvadori, Barbara
    Arrighi, Giada
    Marcucci, Lorenzo
    Filidei, Mario
    Orlandini, Cinzia
    Falcone, Alfredo
    Bevilacqua, Generoso
    Zavaglia, Katia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345